KPIs & Operating Metrics(New)
Growth Metrics

Teva Pharmaceutical Industries (TEVA) Gross Margin (2016 - 2026)

Teva Pharmaceutical Industries filings provide 18 years of Gross Margin readings, the most recent being 49.52% for Q1 2026.

  • On a quarterly basis, Gross Margin rose 128.0% to 49.52% in Q1 2026 year-over-year; TTM through Mar 2026 was 52.07%, a 137.0% decrease, with the full-year FY2025 number at 51.79%, up 305.0% from a year prior.
  • Gross Margin hit 49.52% in Q1 2026 for Teva Pharmaceutical Industries, down from 56.38% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 73.14% in Q4 2024 to a low of 43.21% in Q1 2023.
  • Median Gross Margin over the past 5 years was 48.24% (2025), compared with a mean of 50.14%.
  • Biggest five-year swings in Gross Margin: soared 1893bps in 2024 and later plummeted -1676bps in 2025.
  • Teva Pharmaceutical Industries' Gross Margin stood at 45.57% in 2022, then grew by 19bps to 54.21% in 2023, then surged by 35bps to 73.14% in 2024, then fell by -23bps to 56.38% in 2025, then dropped by -12bps to 49.52% in 2026.
  • The last three reported values for Gross Margin were 49.52% (Q1 2026), 56.38% (Q4 2025), and 51.43% (Q3 2025) per Business Quant data.